Eli Lilly Announces CFO Change
Eli Lilly Announces CFO Change
Shares of Eli Lilly And Company (NYSE:LLY) announced that its Chief Financial Officer, Anat Ashkenazi, has resigned to pursue a new career. Gordon Brooks has been appointed as the interim CFO, effective July 15 2024. The company is actively searching for a permanent replacement.
Lilly and Company股票(NYSE:LLY)的财务总监Anat Ashkenazi宣布辞职，追求新的工作机会。 Gordon Brooks被任命为暂代财务总监，自2024年7月15日起生效。该公司正在积极寻找永久替代人选。
What Else: Additionally, Eli Lilly's shares are being closely watched due to a circulating article highlighting a high number of patients quitting Ozempic, a weight loss drug, due to severe side effects. This issue has impacted the broader market sentiment around weight loss medications, with lawsuits alleging severe side effects like stomach paralysis and blindness according to DailyMail.
其他：此外，由于一篇文章指出大量患者因副作用严重而退出减肥药Ozempic，Eli Lilly的股票受到密切关注。这个问题影响了整个减肥药市场的情绪，据DailyMail报道，有人提出诉讼，称出现了严重的副作用，如胃麻痹和失明。
LLY Price Action: Eli Lilly and Company shares were slightly up, trading 0.80% higher at $940.00 at the time of writing, according to Benzinga pro.
LLY股票价格变动：根据Benzinga Pro的消息，在撰写本文时，Eli Lilly and Company的股票稍微上涨，涨幅为0.80%，报940.00美元。
Photo by rafapress on Shutterstock.
照片来自Shutterstock的rafapress。